HRAS and thyroid gland carcinoma: 5 patients with thyroid nodules carried molecular characteristics such as TERT promoter mutations (n = 1) and BRAF/RAS co-mutations with other genes (BRAFV600E +TP53 n = 1, KRAS+TP53 n = 1, HRAS+TERT n = 1, BRAFV600E +TERT n = 1), which are known to indicate an increased risk of malignancy in thyroid cancer.